Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00618124 · ClinicalTrials.gov registry record · Phase 1
A Study To Find The Best Doses Of SU011248 (Sunitinib) And Capecitabine When These Drugs Are Administered Together
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 77
- Enrollment target
NCT00618124 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 77 participants.
The verdict
NCT00618124, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 77 participants
- Enrollment target
Study Summary
This study assesses the maximum tolerated dose, overall safety and antitumor activity of SU011248 in combination with capecitabine in patients with advanced solid tumors
Interventions
- DRUG SU011248; Capecitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2005-05 |
| Est. Completion | 2008-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00618124
The ClinicalTrials.gov registry entry for NCT00618124 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SU011248; Capecitabine is the first listed.
NCT00618124 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00618124 about?
NCT00618124 is a clinical study titled "A Study To Find The Best Doses Of SU011248 (Sunitinib) And Capecitabine When These Drugs Are Administered Together". This study assesses the maximum tolerated dose, overall safety and antitumor activity of SU011248 in combination with capecitabine in patients with advanced solid tumors
What is the current status of trial NCT00618124?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 77 participants. The study started on 2005-05. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00618124?
The interventions under investigation include: SU011248; Capecitabine (DRUG).
Who is sponsoring clinical trial NCT00618124?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.